PolyPid Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
PYPD Nasdaq 2834 www.polypid.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PolyPid Ltd.

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 - Jul 30th, 2026 6:00 am
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ - Jul 29th, 2026 6:30 am
Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid - Jul 21st, 2026 7:15 am
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada - Jul 21st, 2026 5:30 am
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀ - Jun 1st, 2026 6:30 am
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference - May 20th, 2026 6:30 am
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - May 13th, 2026 5:01 pm
PolyPid Ltd. Q1 2026 Earnings Call Summary - May 13th, 2026 2:58 pm
PolyPid (PYPD) Q1 2026 Earnings Transcript - May 13th, 2026 1:01 pm
PolyPid Q1 Earnings Call Highlights - May 13th, 2026 12:09 pm
PolyPid Q1 2026 Earnings Call: Complete Transcript - May 13th, 2026 7:24 am
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results - May 13th, 2026 5:30 am
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 - May 6th, 2026 6:00 am
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - Apr 28th, 2026 6:30 am
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - Apr 13th, 2026 7:15 am
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - Mar 31st, 2026 6:30 am
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application - Mar 17th, 2026 6:30 am
PolyPid Announces Participation in Upcoming Investor Conferences - Feb 25th, 2026 6:35 am
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit? - Feb 13th, 2026 3:24 am
PolyPid Ltd. Q4 2025 Earnings Call Summary - Feb 12th, 2026 6:30 am